AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more T-shirts are quintessential for any wardrobe, especially during the spring and summer. They're a ...

T-Mobile is the third-largest wireless carrier in the United States, with its popularity largely down to its network coverage and the wide range of tempting offers available. They span from T ...

A pup named Valentina was returned to a shelter just before the holidays, and her heartbroken face has gone viral on social media. "Valentina was returned. She doesn't understand why," reads the ...

American drug major AbbVie Healthcare’s Indian arm, which is under the scanner for sponsoring foreign trips of 30 doctors in violation of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP ...

ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) ...

The Apex Committee for Pharma Marketing Practices has found Abbvie Healthcare India Private Ltd in breach of the UCPMP ( Uniform Code for Pharmaceutical Marketing Practices), by sponsoring ...

The department of pharmaceuticals (DoP) reprimanded AbbVie Healthcare India for unethical marketing practices involving over ₹1 crore spent on foreign vacations for 30 doctors under the guise of ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...

Polaris Global Equity Strategy highlighted stocks like AbbVie Inc. (NYSE:ABBV) in its Q3 2024 investor letter. AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals.